Combined Use of PDE5 Inhibitors and Nitrates in the Treatment of Pulmonary Arterial Hypertension in Patients With Heart Failure-Reference-Cited by-同舟云学术

Combined Use of PDE5 Inhibitors and Nitrates in the Treatment of Pulmonary Arterial Hypertension in Patients With Heart Failure

Published:2009-02 Issue:1 Volume:15 Page:31-34
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Stehlik Josef,Movsesian Matthew A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression;Lincoln;J Appl Physiol,2001

2. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study;Ghofrani;J Am Coll Cardiol,2004

3. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure;Alaeddini;Am J Cardiol,2004

4. Oral sildenafil reduces pulmonary hypertension after cardiac surgery;Trachte;Ann Thorac Surg,2005

5. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide;Michelakis;Circulation,2002

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside;Journal of Clinical Medicine;2024-04-22

2. Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives;Pharmaceuticals;2023-09-06

3. Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease;Current Cardiology Reports;2023-04-19

4. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies;American Journal of Physiology-Heart and Circulatory Physiology;2022-05-01

5. Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension;American Journal of Physiology-Regulatory, Integrative and Comparative Physiology;2021-06-01